CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenues:
Total revenues	$ 215,079	$ 92,933	$ 533,931	$ 136,756
Operating expenses:
Cost of sales	35,741	17,339	62,083	30,201
Research and development	218,480	77,428	337,579	184,539
Selling, general and administrative	250,455	170,057	477,698	329,580
Total operating expenses	504,676	264,824	877,360	544,320
Loss from operations	(289,597)	(171,891)	(343,429)	(407,564)
Other income (expense):
Interest expense	(17,114)	(7,836)	(34,330)	(15,567)
Interest expense on mandatorily redeemable preferred shares	(8,077)	(8,042)	(15,994)	(15,985)
Interest expense on liability related to sale of future royalties	(18,045)	(14,499)	(35,359)	(28,007)
Change in fair value of derivatives	(111,197)	(1,490)	(107,593)	(1,700)
Gain from equity method investment	0	0	0	5,261
Other income (expense), net	2,229	(3,051)	2,310	(4,751)
Total other expense, net	(152,204)	(34,918)	(190,966)	(60,749)
Loss before provision for income taxes	(441,801)	(206,809)	(534,395)	(468,313)
Provision for income taxes	84	4,350	24,387	8,174
Net loss	(441,885)	(211,159)	(558,782)	(476,487)
Net loss attributable to non-controlling interests	498	540	996	900
Deemed dividend upon repurchase of preferred shares in consolidated subsidiary	0	0	(92,673)	0
Net loss attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd.	$ (441,387)	$ (210,619)	$ (650,459)	$ (475,587)
Net loss per share attributable to Biohaven Pharmaceutical Holding Company Ltd - basic (in dollars per share)	$ (6.21)	$ (3.23)	$ (9.20)	$ (7.48)
Net loss per share attributable to Biohaven Pharmaceutical Holding Company Ltd - diluted (in dollars per share)	$ (6.21)	$ (3.23)	$ (9.20)	$ (7.48)
Weighted average common shares outstanding - basic (shares)	71,043,693	65,112,179	70,689,949	63,584,932
Weighted average common shares outstanding - diluted (shares)	71,043,693	65,112,179	70,689,949	63,584,932
Comprehensive loss:
Net loss	$ (441,885)	$ (211,159)	$ (558,782)	$ (476,487)
Other comprehensive loss, net of tax	(3,413)	(129)	(5,738)	(34)
Comprehensive loss	(445,298)	(211,288)	(564,520)	(476,521)
Less: comprehensive loss attributable to non-controlling interests	498	540	996	900
Comprehensive loss attributable to Biohaven Pharmaceutical Holding Company Ltd.	(444,800)	(210,748)	(563,524)	(475,621)
Product revenue, net
Revenues:
Total revenues	193,954	92,933	317,544	136,756
Collaboration and other revenue
Revenues:
Total revenues	$ 21,125	$ 0	$ 216,387	$ 0